Loading patent…
OwnerPaul B. Fisher, Dong-Chul Kang +1inventors
InventorsPaul B. Fisher, Dong-Chul Kang, Zao-Zhong Su
Estimating the term…
The invention provides for isolated nucleic acids encoding Progression Suppressed Gene 13 (PS Gen 13) proteins, vectors comprising said nucleic acids, isolated PSGen 13 proteins, and methods of using such molecules to prevent the growth of cancer cells and/or new blood vessels and accordingly to treat patients suffering from cancer. It is based, at least in part, on the characterization of the complete cDNAs encoding rat and human PSGen 13, and on the discovery that increased levels of PSGen 13 expression can suppress the transformed phenotype and inhibit the activities of promoter elements associated with cancer progression and angiogenesis. In various embodiments, the present invention provides a method for inhibiting growth of a cancer cell which comprises contacting the cancer cell with a nucleic acid encoding a PSGen 13 protein, a PSGen 13 protein or a PSGen 13 activator compound in a sufficient amount so as to inhibit growth of the cancer cell. The invention also provides a method for treating cancer in a subject which comprises contacting a cell of the subject with a nucleic acid encoding a PSGen 13 protein in a sufficient amount so as to cause the cell to express the PSGen 13 protein, thereby treating cancer in the subject.
An isolated nucleic acid encoding a Progression Suppressed Gene 13 protein, operably linked to a promoter element active in eucaryotic cells.
An isolated nucleic acid encoding a rat Progression Suppressed Gene 13 protein and having a nucleic acid sequence as set forth in SEQ ID NO:
An isolated nucleic acid encoding a human Progression Suppressed Gene 13 protein and having a nucleic acid sequence as set forth in SEQ ID NO:3, operably linked to a promoter element active in eucaryotic cells.
An isolated nucleic acid encoding a protein having an amino acid sequence as set forth in SEQ ID NO:2.
An isolated nucleic acid encoding a protein having an amino acid sequence as set forth in SEQ ID NO:4.
An isolated Progression Suppressed Gene 13 protein.
An isolated Progression Suppressed Gene 13 protein having an amino acid sequence as set forth in SEQ ID NO:2.
An isolated Progression Suppressed Gene 13 protein having an amino acid sequence as set forth in SEQ ID NO:4.
A method for suppressing the transformed phenotype of a cell, comprising administering, to the cell, an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method for inhibiting cancer cell growth, comprising administering to said cancer cell an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method of inhibiting angiogenesis in a tumor, comprising administering to the tumor an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method of treating cancer in a subject, comprising administering, to the subject, an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method for suppressing the transformed phenotype of a cell, comprising administering, to the cell, an effective amount of a Progression Suppression Gene 13 protein.
A method for inhibiting cancer cell growth, comprising administering to said cancer cell an effective amount of a Progression Suppression Gene 13 protein.
A method of inhibiting angiogenesis in a tumor, comprising administering to the tumor an effective amount of a Progression Suppression Gene 13 protein.
A method of treating cancer in a subject, comprising administering, to the subject, an effective amount of a Progression Suppression Gene 13 protein.
A method for suppressing the transformed phenotype of a breast cancer cell, comprising administering, to the cell, an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method for inhibiting breast cancer cell growth, comprising administering to said cancer cell an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method of inhibiting angiogenesis in a breast tumor, comprising administering to the tumor an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method of treating breast cancer in a subject, comprising administering, to the subject, an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method for suppressing the transformed phenotype of a prostate cancer cell, comprising administering, to the cell, an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method for inhibiting prostate cancer cell growth, comprising administering to said cancer cell an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method of inhibiting angiogenesis in a prostate tumor, comprising administering to the tumor an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method of treating prostate cancer in a subject, comprising administering, to the subject, an effective amount of a nucleic acid encoding a Progression Suppression Gene 13 protein, in expressible form.
A method for identifying a human cancer cell target for treatment with HuPSGen 13 comprising detecting a deletion in chromosomal region 6q23.2-6q23.3.
A method of identifying an individual with an increased risk of developing a cancer, comprising detecting, in the individual, a deletion in chromosomal region 6q23.2-6q23.3.
A method of detecting progression of a cancer in a subject comprising detecting, in the individual, a deletion in chromosomal region 6q23.2-6q23.3.
Dependencies are inferred from the claim text.